Wiley Matthew T. 4
4 · BioXcel Therapeutics, Inc. · Filed Apr 8, 2024
Insider Transaction Report
Form 4
Wiley Matthew T.
Other
Transactions
- Sale
Common Stock
2024-04-04$2.64/sh−1,008$2,656→ 2,992 total - Exercise/Conversion
Restricted Stock Units
2024-03-15+3,000→ 9,000 total→ Common Stock (3,000 underlying) - Exercise/Conversion
Common Stock
2024-03-15+3,000→ 3,000 total
Footnotes (4)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.
- [F3]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $2.62 to $2.6502. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F4]The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.